We are seeing how big the Imugene story can be with
the increasing flow of information which is becoming available.
In 2019 Merck bought out Arqule an oncolgy company, whose
promising drug ARQ531 was in a Phase 2 expansion study for
treatment of B cell malignancies. Merck paid shareholders $20 US
per share cash and the prior share price was $4-5.00 US
We are seeing how big the Imugene story can be withthe...
-
- There are more pages in this discussion • 13,205 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.2¢ |
Change
-0.001(1.89%) |
Mkt cap ! $382.1M | |||
| Open | High | Low | Value | Volume |
| 5.3¢ | 5.4¢ | 5.2¢ | $216.1K | 4.106M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 31 | 1854997 | 5.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 5.3¢ | 382882 | 4 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| IMU (ASX) Chart |